Merck & Co Inc
XSGO : MRK$128.40+0.00%latest daily quote
Financials
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
USD · reported units. Click a value to inspect its source.
| Reported line item | Apr 1, 2026 to Jun 30, 2026 (current) | Jan 1, 2026 to Jun 30, 2026 | Apr 1, 2025 to Jun 30, 2025 | Jan 1, 2025 to Jun 30, 2025 |
|---|---|---|---|---|
| Income Statement [Abstract] | ||||
| Sales | ||||
| Costs, Expenses and Other | ||||
| Cost of sales | ||||
| Selling, general and administrative | ||||
| Research and development | ||||
| Restructuring costs | ||||
| Other (income) expense, net | ||||
| Total Costs, Expenses and Other | ||||
| (Loss) Income Before Taxes | ||||
| Income Tax Provision | ||||
| Net (Loss) Income | ||||
| Less: Net (Loss) Income Attributable to Noncontrolling Interests | ||||
| Net (Loss) Income Attributable to Merck & Co., Inc. | ||||
| Basic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)USD / share | ||||
| (Loss) Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)USD / share |
14 line items · 4 reported periodsOriginal filing order · parentheses indicate negative amounts
Each column reflects this filing’s presentation. Original line items and period dates are preserved.